{"url_path":"/sec/spro/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-277506-index.html","accession_number":"0001193125-26-277506","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-277506-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":191,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure\n\nOn June 17, 2026, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted approval for Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of complicated urinary tract infections (“cUTIs”), including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment option.\n\nThe full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.\n\nThe information in this Item 7.01 and Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing."}